AEON Biopharma, Inc. (NASDAQ:AEON – Free Report) – Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of AEON Biopharma in a report released on Wednesday, April 17th. HC Wainwright analyst D. Tsao anticipates that the company will post earnings of ($0.29) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for AEON Biopharma’s current full-year earnings is ($1.54) per share. HC Wainwright also issued estimates for AEON Biopharma’s Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.32) EPS and Q4 2025 earnings at ($0.24) EPS.
AEON Biopharma (NASDAQ:AEON – Get Free Report) last posted its quarterly earnings data on Friday, March 29th. The company reported ($0.71) earnings per share for the quarter.
AEON Biopharma Price Performance
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. Atalaya Capital Management LP acquired a new stake in shares of AEON Biopharma in the third quarter valued at about $19,827,000. Formidable Asset Management LLC bought a new stake in AEON Biopharma during the third quarter worth $360,000. Vanguard Group Inc. bought a new position in AEON Biopharma during the third quarter worth about $1,085,000. Finally, Northern Trust Corp lifted its position in shares of AEON Biopharma by 53.4% in the fourth quarter. Northern Trust Corp now owns 49,819 shares of the company’s stock valued at $359,000 after buying an additional 17,341 shares during the last quarter. Institutional investors and hedge funds own 22.78% of the company’s stock.
About AEON Biopharma
AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.
Read More
- Five stocks we like better than AEON Biopharma
- The “How” and “Why” of Investing in 5G Stocks
- Comprehensive PepsiCo Stock Analysis
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- What Does Downgrade Mean in Investing?
- Bear Market Funds to Watch This Year
Receive News & Ratings for AEON Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEON Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.